ADC Therapeutics SA

ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield

ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company

ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting

ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting

ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer

ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research

ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

ADC Therapeutics and Freenome Enter Biomarker Development Collaboration

ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial

ADC Therapeutics Announces Final Close of Series E Financing Expansion

ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics Announces Completion of a Series E Financing Expansion

ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma

ADC Therapeutics and Adagene Announce License Agreement

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI(R) (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma

ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors

ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors

ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma